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Summary.-Using a microassay for cellular immunity, tumour specific cytotoxicity
was detected in 2/5 cases of ocular melanoma and 1/3 cases of primary cutaneous
melanoma before treatment. Reactivity was measured against allogeneic skin
melanoma target cells in short or long term in vitro culture. Lymphoid cells from
patients with disseminated cutaneous melanoma were either non-reactive (4/8
cases) or gave a nonspecific cytotoxicity on target cells of diverse histogenic origins.
Among tumour-free patients tested after surgery, 0/2 patients with ocular tumour
were non-reactive 3-4 months post surgery. After surgical excision of cutaneous
melanoma, 2/2 patients gave tumour specific reactions during the first month after
surgery. After longer time intervals, from 5 months to 3 years, only 1/8 patients
were reactive.
Preoperative radiotherapy in a total skin dose of 10,000 rad produced a transient
tumour specific reaction 24 h after therapy in a single case. Following local tumour
excision in patients given preoperative irradiation, 2 cases which had previously
demonstrated tumour specific CMI lost reactivity. Among 14 tumour-free indivi-
duals tested only after preoperative radiotherapy and surgery, at intervals from 5
days to 13 years, a single case gave tumour specific CMI.
Palliative irradiation in doses 4000-4960 rad to the inguinal or axillary lymph
nodes was found to induce a generalized lymphopenia within 48 h after treatment.
Lymphoid cell preparations from patients with localized melanoma contained
significantly increased numbers of immature cells (lymphoblasts and myeloblasts)
and myeloid precursor elements. Those prepared from patients with disseminated
disease had in addition elevated levels of eosinophils but reduced numbers of
recoverable lymphocytes.
IMMUNITY to malignant melanoma
has been the subject of numerous in
vitro studies. Specific antigen(s) unique
to melanoma cells have been detected
using assays for both cellular and humoral
immunity (Currie, Lejeune and Fairley,
1971; Currie, 1973; Cochran et al., 1973;
de Vries, Riimke and Bernheim, 1972;
Fossati et al., 1971; Hellstrom et al.,
1971, 1973a, b; Heppner et al., 1973;
Jehn, Nathanson and Schwartz, 1970;
Morton et al., 1968, 1971; Lewis et al.,
1969). Qualitatively, these assays have
usually demonstrated common antigen(s)
in melanoma target cells derived from
different donors. Discordant results be-
tween melanoma cells from different
donors have also been reported, which
could indicate the presence of unique
antigen(s) in a given tumour (de Vries et
al., 1972; Fossati et al., 1971; Lewis et
al., 1969).
Quantitatively, the humoral response
to melanoma has been shown to correlate
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with extent of disease (Morton et al.,
1968; Lewis et al., 1969). A diminution
in detectable cellular immunity has also
been reported in some melanomapatients
with advancing disease (Cochran et al.,
1973; de Vries et al., 1972; Hellstrom et
al., 1973a, b; Heppner et al., 1973).
The present article represents an
attempt to quantitate the cellular response
to tumour in patients with skin or ocular
melanoma, to determine its incidence in
different stages of disease, and in patients
clinically tumour-free after local surgery
or preoperative radiotherapy.
MATERIALS AND METHODS
Melanoma patients.-33 cases of clinically
verified or suspected malignant melanoma
were studied. The site of origin of the
tumour and sex distribution ofthese patients
are presented in Table I Appendix. The
clinical details ofthe patients with malignant
melanoma or melanosis of the eye are given
in Table II Appendix. Malignant melanoma
of the skin was staged according to extent
of tumour spread, as shown in Table III of
the Appendix. Details of surgery and
radiotherapy techniques used in treatment
of melanoma and transitional cell carcinoma
of the urinary bladder are given in the
Appendix.
Clinical controls.-Table IV Appendix
summarizes 42 patients with unrelated neo-
plasms tested in parallel with the melanoma
patients in this series. In addition, 10
normal healthy controls were included.
Clinical details ofthese patients are presented
in the Appendix.
Cell mediated immunity.-CMI was as-
sayed as described previously for patients
with carcinoma of the urinary bladder
(O'Toole, 1973; O'Toole et al., 1972a, b,
1973a, b, 1974). Twenty-four separate experi-
ments were carried out; all blood samples
were received coded and the code was not
broken until the residual target cell numbers
had been calculated.
Effector cells.-These were prepared rou
tinely as follows: 20-50 ml of defibrinated
blood were obtained from each donor. The
bulk of the erythrocytes were sedimented
over 3% gelatin w/v in Tris buffered Hanks'
solution (Coulson and Chalmers, 1964), for
1 h at 37°C. The leucocyte plasma super-
natant was transferred to a nylon wool
column and incubated for 30 min at 37°C, to
remove adherent cells (Greenwalt, Galewski
and McKenna, 1962). The cells were eluted
from the column and washed 3 times with
Tris buffered Hanks' solution containing
2.5% heat inactivated foetal calf serum
(TH). The remaining erythrocytes were
lysed by exposure to 0.83% Tris-ammonium
chloride solution at 4°C for 5-10 min (Boyle,
1968). The cells were then spun down and
washed a further 3 times in TH. Cyto-
centrifuge (Dore and Balfour, 1965) pre-
parations made from each donor's " purified "
effector cells were stained with May-Grin-
wald Giemsa. Differential counts were made
based on a minimum of 500 cells/preparation
(Table V).
Target cells.-Primary cultures were estab-
lished from explants of metastatic skin
melanomata. MEL-I from a draining lymph
node of patient S.M. in passages 1-24 pro-
vided target cells in 22 experiments. These
cells were epithelioid in appearance and
produced tumours in nude mice (E. Kristen-
sen and J. Kieler, personal communication).
A melanoma cell line RPMI 7931 derived
from metastatic cutaneous melanoma (estab-
lished by R. Gerner and G. Moore) was used
in 13 experiments. The following non-
melanoma target cells were used: the cell
strain J82 derived from TCC in passages
2-32; the established cell lines from TCC,
T24 (Bubenik et al., 1973), RT4 (Rigby and
Franks, 1970) and from non-malignant
bladder HCV-29 (established by J. Fogh).
The pattern of tumour specific reactions by
lymphoid cells from patients with TCC on
these lines has been described in detail
previously (O'Toole, 1973; O'Toole et al.,
1972a, b, 1973a, b, 1974). All cultures were
maintained intissue culture medium 199, with
Hanks' salts containing 10% heat inactivated
calf serum, with 100 i.u. penicillin, 100 ,ig
foetal streptomycin and 0 3 mg glutamine/ml.
The tissue culture passage number (TC)
is presented for the primary cell cultures
for each experiment reported in the results
section.
Microcytotoxicity assay.-This was based
on that described by Takasugi and Klein
(1970). Target cells were prepared from
monolayer cultures in exponential growth
phase by treatment with a solution of
0 02% EDTA + 0.050% trypsin. The cells
were washed 3 times in tissue culture medium
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and seeded into Falcon 3034 microplates.
Cell attachment was usually completed after
incubation for 3-4 h at 37°C, in humidified
air + 5% CO2. The plates were then in-
verted for 20 min and the medium drained
off. Effector cell preparations suspended
in tissue culture medium supplemented with
10 mmol/l Hepes buffer were added in 15 pul
volumes to give the required effector: target
cell ratios. Each effector cell preparation
was tested at 2 ratios. A minimum of 12
wiells was used for each parameter under
test, including the effector cell-free medium
control.
The plates wrere incubated at 37°C in
humidified air + 500 CO2 for 40-48 h
(preliminary experiments showed that signi-
ficant cytotoxicity wras not routinely de-
tected before this time). Experiments were
terminated byinverting the plates for 20 min,
draining off the medium, washing with
phosphate buffered saline pH 7-2 and staining
with May-Griinwald Giemsa.
Calculation of cytotoxicity. The arith-
metic mean of residual targets in wells
which had contained patients' lymphoid
cells was compared with that in wells having
contained control donors' cells at equivalent
ratios. The significance of differences w-ere
estimated by Student's t test with P < 0 05.
Cytotoxicity is expressed as percent
reduction (1 -P/C) x 100; P = inean resi-
dual targets after incubation with patient's
lymphoid cells; C = mean residual targets
after incubation with control donor's lymph-
oid cells; at equivalent concentrations.
Tumour specific cytotoxicity refers to
a significant effect produced by a given
donor's effector cells only on targets of
a common histogenic origin. Nonspecific
cytotoxicity is defined as an effect on targets
of more than one histogenic origin.
RESULTS
Conmposition of effector cell preparations
Differential counts were made on the
"purified " effector cell preparations from
each blood donor. The pooled data for
each patient group and clinical situation
are shown in Table I. The significance
of differences from normal healthy control
donors was estimated by Student's t test.
Patients with localized malignant melan-
oma (both ocular and skin) were found
to have significantly more immature and
myeloid precursor elements in the blood.
Melanoma patieints with widespread meta-
stases had in addition increased numbers
of eosinophils and significantly fewer
recoverable lymphocytes. Patients clini-
cally " cured " of melanoma showed no
significant changes from normals. Among
the clinical control donors patients with
localized carcinoma of the bladder (TCC)
also had increased numbers of immature
TABLE I. Cellular Content ofEffector Preparations* (mean percentage ± SD)
Patient grouip
MIelanoma localize(1
Mtelanoma tutmour-
free
AMelanorna
metastases
Ca blad(ler
localize(c
Ca bladcler
tumouLr-firee
post radiatiuii
Ca blad(ler
metastases
Basal cell Ca
:Normal healthy,
Lympho-
cytes
92 8±6 8
Neutro-
phils
19 92 24
Eosino-
phils
2 5±.3 8
94 7±'+30 1-4-2 1 74-1-6
88-6±8 2-8--3
(0 05)t
96 5±2 1±1
93-5±5-7 0-9l -3
74± 12
(<0-001)t
95 7±4 6
4-6±4- 6
(0 05)t
0-40- 5
(0-02)t
2 7X4 9
Immature Pro-
Basophils AMonocytes cells myelocytes
1 5+1-8 0 2+0-4 0-6±0-9 0-6±1-1
(<0 05)t (<0 05)t
1*7d41-7 0 17±0-2 0-2±0 5 0-07±+016
1-58 2
0-9 0-6
2-4-1 6
5 -65-7 15- 16 2-312-5
(0-05)t (0 05)t
2-4±3-8 0-7±1-1 0-8±0- 5
95±3 1-2±1-5 2-2±1-8 1-6±1-9
0-3-'0-4
0- 26±0 28
0-2±0 24
0L2-LO0-4
O
(0-05)t
0:3±L0-36
0-8±1 -3
(<0 .05)t
0-46±0- 6
(0-05)t
0 45±0 6
(O .05)t
0 7±O 7
(0-05)t
0-2±0 25
0- 08±0 22
1±1-5
(0 05)t
0-5± 1-3
(0 05)t
0-3±0- 6
2-7±5-6
(<0-05)t
0
0-028±0 07
* Cells prepared as dlescribed in MKaterials anid M(-ethods.
t Significantly (lifferent from inormal (lonors.
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TABLE II. Nonspecific Cytotoxicity ofEffector Cellsfrom Patient A.R. with
Metastatic Tumour
Effector: Target Sturviving targets/well
Effector ratio (mean±SD)
(1) J 126 500:1 16+6
250 :1 24±10
(2) S.M. auitologous 500 1 24±4
250 :1 26±6
(3) A.R. 500 1 4±2
250:1 4±2
(4) E.H. 500 1 24±6
26±8
T24 J 126
S.M.
A.R.
E.H.
500: 1
250 : 1
500: 1
250: 1
500: 1
250 : 1
500: 1
250: 1
143±59
184±90
152±60
201 ±51
49±14
98± 78
179± 78
267±49
% Reduction (5)
0
0
75
83
0
0
0
0
66
47
0
0
Medium control mean ± SD MEL-1, 28 ± 4 T24, 263 ± 72.
* MEL-1 derived from metastatic tumour of patieint S.M.
(1) Untreated Ca prostate.
(2) S.M. malignant melanoma skin with lymph node and brain metastases.
(3) A.R. malignant melanoma skin with liver metastases.
(4) E.H. malignant melanoma skin tumour-free 6 years after preoperative ra(liotherapy and surgery.
(5) % Reduction estimated on J 126. Incubation time 45 h.
and myeloid precursor cells but decreased
numbers of eosinophils in their effector
cell preparations. Patients with meta-
static TCC had in addition elevated
numbers of eosinophils and neutrophils
but much reduced numbers of recoverable
lymphocytes. Tumour-free TCC patients
post radiotherapy, differed from normal in
having a still elevated level of immature
cells. Patients with basal cell carcinoma
differed from normals in having no detect-
able monocytes intheireffector cell prepar-
ations. Patients with carcinoma of
prostate or renal pelvis were too few for
a separate statistical analysis; however, all
patients with metastases showed a related
picture to that observed in melanoma and
TCC patients in the same stage.
Nonspecific cytotoxicity
A significant reduction in the number
of surviving targets from more than
one histogenic origin was observed with
effector cells from 4/8 patients with
metastatic malignant melanoma (this in-
cluded one patient with amelanotic dis-
ease). This type of reaction is shown
in Table II; the patient A.R. gave a
significant effect on melanoma, non-
malignant bladder and TCC targets at
3 separate testings during a period of
1 year. Similarly, 4/6 patients with
widespread metastatic TCC showed sig-
nificant effects on both TCC and melanoma
targets. All other melanoma patients
with metastatic tumour showed no effect
on any target tested; this is exemplified
by S.M. in Table II who failed to respond
against her own autologous cells (MEL-1)
and against an allogeneic target T24.
The correlation of nonspecific effects to
metastatic disease could indicate a role
for the contaminating non-lymphocytic
elements in these effector preparations.
Significant nonspecific cytotoxicity was
observed consistently in only one other
patient group; 3/6 untreated patients
with basal cell carcinoma gave this type
of reaction. Clearly from Table I this
effect does not relate to the purity of
the effector cell preparations or to therapy
effects in this group.
Target*
MEL-1
T.C.5
p
<0-001
<0*001
<0-001
0-02
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TABLE IV.-Effect ofPreoperative Radiotherapy and Surgery on Tumour Specific
Cytotoxicity ofEffector CellsfromPatient W.M. with Malignant Melanoma ofSkin
Target Effector
T24 (1) W.M.
(2) J 145
(3) J 145 A
14.2.73
untreateed
MEL-1 W.M.
TC5
J 145
J 145A
T24 W.M.
(4) J.A.
(5) J 146 A
15.2.73
24 h after
10,000 rad
MED-1 W.M.
TC5
J.A.
J 146A
T24 W.M.
(6) J 153
21.2.73
5 days post
excision
MEL-1 W.M.
TC5
J 153
T24 W.M.
(7) J 230
16.4.74
1 year after
excision
MEL-1 W.M.
TC26
J 230
RPMI W.M.
7931
J 230
Effector Target
ratio
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
250 1
125 1
500 1
250 1
500 1
250 1
500 1
250 1
500 1
250 1
500 1
250 1
500 1
250 1
Surviving
targets/well
(mean±SD)
163±31
177±29
95±31
142±26
150±20
169±27
130±25
150±40
150±30
170±50
140±19
160±30
76±10
80±10
64±13
75±9
70±11
76±9
70±30
80±30
140±30
160±40
146±26
156±40
78±7
90±22
74±18
76±12
33±12
31±6
27±5
29±5
139± 14
150±46
144±30
146±25
634±19
84±15
49±15
55±10
55±12
70±6
50±11
51±8
% Reduc-
M.C.* tion (8)
0
0
178±28
3
7
6
150±30 °
0
0
78±11 9
52
160±45 49
3
2-5
86±16 0
0
29±11 0
0
144±23 3-5
68±16 0
Q
67±9 0
0
* M.C. Medium control targets incubated without lymphocytes.
(1) W.M. Malignant melanoma skin, stage I.
(2) J 145. TCC TIMI untreated.
(3) J 145. A normal donor.
(4) J.A. Malignant melanoma skin, stage I. Four months after preoperative radiotherapy and tumour
excision, clinically tumour-free.
(5) J 146. A normal donor.
(6) J 153. Basal cell ca, 1 month after local radiotherapy.
(7) J 230. Normal donor.
(8) % Reduction estimated on normal donors and J 153.
NS. Differences not significant.
p
<0-001
<0-01
NS
NS
NS
NS
0-001
0-001
NS
NS
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TABLE IV.-Effect ofPreoperative Radiotherapy andSurgery on Tumour Specific
Clytotoxicity ofEffector CellsfromPatientS.G. with Malignant Melanoma ofSkin
Target Effector
RPMI 7931 (1) S.G.
(2) J 174
(3) J 174 A
T24
30u4.73
untreated
SG.
J 174
J 174A
RPMI 7931
(4)
(5)
T24
RPMI 7931
(6)
(7)
SG.
J 176
J 176A
3.5.71
48 h after
10,000 rad
SG.
J 176
J 176A
SG.
J 178
J 179A
MEL-1 TC20 SG.
J 178
J 178 A
T24 SG.
J 178
J 178A
14.5.73
10 days post
excision
Effector: Target
ratio
250 1
125 1
250 1
125 1
250 : 1
125 1
250 1
125: 1
250 1
125 1
250 1
125: 1
250: 1
150 1
250 1
150 : 1
250 1
150 1
250 1
125 1
250 1
125: 1
250 1
125 1
500: 1
250: 1
500 : 1
250: 1
500: 1
250: 1
500: 1
250: 1
500: 1
250: 1
500: 1
250 : 1
500: 1
250: 1
500: 1
250: 1
500: 1
250: 1
Surviving
targets/well
(mean+SD) M.C.*
8+4
13+5
13+5 22+6 15+4
14+6
12+5
17+4
20+6
18+4
19+4
16+5
18+6
17+8
28+ 11
21+3
26+5
20+6
27+8
26+8
30± 11
17+5
26+4
27+6
28+9
63+11
74+9
62+11
74+6
60+10
70+ 12
43+5
38+7
36+8
40+7
38+10
41+8
20+10
24+5
25+7
24+8
22+8
26+ 10
20+5
% Reduc-
tion (8)
43
0
7
0
0
0
0
0
26
0
30+10 9
4
4
0
28+1 23l7 7
88+9
32+7
38+16
0
0
0
0
0
7
5
2
9
8
0
8
* Medium control targets incubated without lymphocytes.
(1) SG. Malignant melanoma skin, stage I.
(2) J 174. TCC T3M4, tumour recurrence post radiotherapy.
(3) J 174 A. Normal donor.
(4) J 176. TCC T3M3, untreated.
(S) J 176 A. Normal donor.
(6) J 178. TCC T3M3, post radiotherapy, large tumour present.
(7) J 178 A. Normal donor.
(8) % Reduction estimated on normal donor in each test. Incubation time 48 h.
N.S. Differences not significant.
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p
0.01
NS
0*05
NS
NS
NS
0 05
NS
NS
NS
NS
NS
NS
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TABLE V.-Tumour Specific Reactions ofSkin Melanoma Patients Tested After
Treatment
Target Effector
MEL-1 TC3 (1) J 97
(2) E.A.
(3) H.B.
(4) S.K.
(5) J 101
(6) J 102
1 T24 J 97
E.A.
H.B.
S.K.
J 101
J 102
RT4 J 97
E.A.
H.B.
S.K.
J 101
J 102
Effector Target
ratio
500: 1
250 : 1
500: 1
250 : 1
500 : 1
250 : 1
500: 1
250 1
500: 1
250 : 1
500: 1
250 : 1
500: 1
250: 1
500: 1
250: 1
500 : 1
250: 1
500: 1
250: 1
500 : 1
250: 1
500: 1
250: 1
500: 1
250: 1
500: 1
250: 1
500: 1
250 : 1
500 : 1
250: 1
500: 1
250: 1
500: 1
250: 1
Surviving targets/well
(mean±SD)
70±30
140±50
30±15
110±40
90±30
130±30
0
70±20
120±45
160±50
60±20
130±25
91± 17
107±18
82±8
93±13
100±15
116± 14
81±10
91±11
84±9
94±19
54± 12
73±19
38±8
38±6
34±12
34±8
48±8
54±10
52±8
54± 12
38±16
38±8
22±6
18±6
Medium control: Targets incubated without lymphocytes (mean ± SD) MEL-1, 160 ± 50; T24,
119 ± 20; RT4, 51±15.
(1) J 97. Tumour cutis capillitii, untreated.
(2) E.A. Malignant melanoma of skin stage I, 2 years after primary operation, 1 month after extended
surgery, clinically tumour-free.
(3) H.B. Malignant melanoma of skin, stage III, 8 months after preoperative radiotherapy and
surgery, metastases.
(4) S.K. Malignant melanoma of skin, stage I, 15 years after preoperative radiotherapy and surgery,
12 years after extended excision, clinically tumour-free.
(5) J 101. Basal cell Ca. untreated.
(6) J 102. TCC T2 M4, 2 months after 6-457 rad, tumour-free.
(7) % Reduction estimated on J 97. Incubation time 40 h.
N.S. Differences not significant.
Tumour specific cytotoxicity
This type of reaction was observed
on both the primary culture MEL-1
and the cell line RPMI 7931 derived
from metastatic malignant skin melan-
oma, by effector cells from certain donors
with tumour of the same histogenic
origin, with no effect on unrelated targets
tested in parallel. Specific reactions were
concurrently observed by effector cells
% Reduction
57
21
0
7
100
50
0
0
14
7
10
13
0
0
11
15
8
12
41
32
10-5
10-5
0
0
0
0
0
0
42
53
p
001
NS
NS
0001
0-01
NS
NS
NS
NS
NS
NS
NS
NS
0-001
0-001
NS
NS
0-01
0-001
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from donors with TCC only on TCC
targets with no effect on melanoma
targets (Tables III, IV, V).
Clinical observations in relation to CMI
Ocular tumour.-The reactions ob-
tained with effector cells from this group
of patients are depicted in Table VII.
Of the 5 patients tested before surgery,
2 showed melanoma specific reactions on
targets derived from skin melanoma.
Quantitative data on patient L.B. are
given in Table VI. Significant effects
were produced on both allogeneic melan-
oma targets, MEL-1 and RPMI 7931,
with no effect on J82, a histogenically
unrelated allogeneic target. In the same
experiment, effectors from patient J.L.
(stage I skin melanoma) showed the
same range of specificity as LB's cells
while effectors from S.O., a patient with
metastatic skin melanoma, produced non-
specific effects.
Effect of surgery on CMI in patients
with ocular tumours.-Only 2 patients
were tested after surgery, at a 3-4 month
interval; both failed to respond (Table
VII). Patient F.E. had also been tested
before operation and showed a nonspecific
effect at that time. The only detectable
difference in F.E.'s effector cell prepara-
tions was that 1% immature cells which
were present before surgery were absent
at test 4 months after treatment.
Malignant melanoma of the skin.
Among 3 patients tested before therapy
(Table VIII) 1 case with stage I tumour
showed a tumour specific reaction. The
remaining patients with this diagnosis
were all tested after treatment.
Effect of preoperative radiotherapy and
surgery on CMI.-As shown in Table
VIII, 3 patients were tested serially to
assess the effect ofthis therapy. Changes
in reactivity were seen in 2 cases-W.M.
and S.G.-during and after therapy.
Detailed quantitative data on the changes
in tumour specific CMI in these patients
are given in Tables III and IV. It can
be seen that both patients showed a
response during a 24-48 h interval after
local irradiation to the tumour. (In the
TABLE VI.-Tumour Specific Cytotoxicity ofEffector Cellsfrom Donors with Skin
or Eye Melanoma
Target* Effector
MEL-1 TC15 (1) LB
(2) JL
(3) J 215
(4) SO
RPMI 7931
J82 TCIO
LB
JL
J 215
S.O.
LB
JL
J 215
S.O.
Effector: Target
ratio
250 : 1
250 :1
250: 1
250: 1
250: 1
250 :1
250 :1
250: 1
250: 1
250: 1
250: 1
250: 1
Surviving
targets/well
(mean±SD)
90±30
70±30
110±20
100±25
35±10
37±4
51±6
26+3
63±12
63±17
58+13
48±12
% Reduction (5)
18
36
9
31
27 -5
49
0
0
17
* For Origin see Materials and Methods.
Medium control: targets incubated without lymphocytes (mean ± SD), MEL-1, 120 ± 4; RPMI 7931,
40 + 3; J 82, 68 + 4.
(1) LB. Melanosis oculi before operation.
(2) JL. Stage I skin melanoma, 3 weeks after operation, clinically tumour-free.
(3) J 215. TCC T3M4, 2 weeks after 4000 rad.
(4) S.O. Skin melanoma with hepatic and lymph node metastases.
(5) % Reduction estimated on control lymphocyte donor J 215; incubation time 48 h.
N.S. Difference not significant.
p
0*05
<0-001
NS
0*05
0*05
<0-001
0*05
308RESPONSES IN PATIENTS WITH OCULAR AND SKIN MELANOMA
TABLE VII.-Summary of CMI in Patients with Ocular Melanoma
Tumour location
Epibulbar
Epibulbar**
Intraocular
Intraocular
Intraocular
Intraocular
Incidence tumour
specific CMI
Patient*
S.T.
L.B.
F.L.
F.E.
M.A.
F.S.
Surgery
AA
Before After
0 (1) NT
+ NT
NT 3 months 0
Nonspecific 4 months 0
O NT
+ NT
2/5 0/2
Clinical situation
Tumour-free after surgery
Tumour-free after surgery
(1) 8 years after local resections and post-operative radiotherapy.
* For clinical details see Appendix Table II.
** Epibulbar location: melanosis in the conjunctiva.
NT Not tested.
TABLE VIII.-Summary of CMI in Patients with Malignant Melanoma of the Skin
Tested Before and After Treatment by Preoperative Radiotherapy and Surgery
Tumour stage Patient
I W.M.
G.G.
S.G.
After Post
Untreated radiotherapy surgery
0 24h+ 5 days 0
1 year 0
0 NT 4 months 0
+ 48h+ 10daysO
Clinical situation
post therapy
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Incidence of tumour
specific CMI
1/3 2/2
NT: Not tested.
case W.M. no reaction had been detectable
before therapy.) The 3 patients were
tested after surgery and all showed no
response; only W.M. was tested more than
once after surgery.
A further 10 patients who received
preoperative radiotherapy and surgery
were available for testing only post
therapy. The observations on this group
are summarized in Table IX. Patients
in stages I and II were clinically tumour-
free, but a single case H.B. with stage
III disease had distant metastases. As
shown in Table IX, only 1 patient, S.K.,
in this series gave tumour specific reac-
tions. Clinically, S.K. appears tumour-
free 13*5 years after therapy. Specific
responses were detected in tests performed
12 and 13 years after therapy. Quantita-
tive details of one test on S.K. are given
in Table V. Experimental details on
patients E.H. and J.A. are given in
Tables II and III respectively. Patient
H.B. was tested in the same experiment
as S.K. and showed no response. Clearly
patients in this group should undergo
further serial testing to access possible
clinical significance of tumour specific
CMI.
Effect oflocal tumour excision on CMI.
No patients were tested both before
and after local surgery, but 12 cases were
available after treatment. These are sum-
marized in Table X. All patients with
a stage I diagnosis were clinically tumour-
free post surgery. Tumour specific reac-
tions were detected in the 2 patients
tested 3-4 weeks after surgery. (Details
of patient E.A. are given in Table V.)
With 1 exception (patient G.A.), all the
remaining cases with stage I tumour
tested at longer time intervals (5 months-
3 years) after surgery showed no reaction.
As with melanoma patients tested after
0/3
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TABLE IX.-Summary of CMI in Patients with Skin Melanoma Tested After
Preoperative Radiotherapy and Surgery
Tumour stage Patient
I M.A.
J.Ar.
J.La.
G.A.S.
W.E.
L.S.
E.H.
S.K.
II F.E.
Time after
treatment
4 months
4 months
1 year
6 months
7 months
4 years
5 years
6 years
12 years
13 years
Clinical situation
CMI after treatment
O Tumour-free
0 Tumour-free
0
0
0
0
0
±
±
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
2 months* 0 Tumour-free
III H.B.
Incidence of tumour
specific CMI
8 months 0 Metastases
1/10
* Patient received post-operative radiotherapy 1 month after surgery.
TABLE X.-Summary of CMI in Patients with Skin Melanoma Tested After
Surgery
Time after
operation
3 weeks
4 weeks
5 months
1 year
2 years
3 years
2 years
3 years
2 years
3 years
Tumour stage Patient
I J.L.
E.A.
N.E.
J.A.
G.A.
A.E.
L.A.M.
O.A.M.
II P.G.
S.M.
III S.O. 3 weeks
6 months
A.R. 14 days*
1 month
1 year
Incidence of tumour
specific CMI
* Tested before palliative radiotherapy.
other types of therapy, periodic retesting
is required to define the clinical signifi-
cance of this response. Patients in this
group with higher stage tumours all had
metastases at time of test. Non-reactive
patient S.M. ispresented in Table II. The
CMI
± +
0
0
0
0
0
0
0
Clinical situation
after treatment
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
Tumour-free
1 week Nonspecific Metastases
1 month 0 Metastases
Nonspecific
0
Nonspecific
Nonspecific
Nonspecific
3/12
Metastases
Metastases
nonspecific effect produced by A.R.'s
andS.O.'s cells arequantitated in Tables II
and VI.
Systemic effects of local radiotherapy.-
Three patients with stage II and III
melanoma were given palliative radio-
310RESPONSES IN PATIENTS WITH OCULAR AND SKIN MELANOMA
therapy in total doses of 4000-4960 rad
to the draining lymph nodes. The result-
ing effects on the detectable numbers of
peripheral lymphoid cells are shown in
Table V Appendix. A drastic lympho-
penia was apparent within 48 h of cessa-
tion of therapy. Similarly, effects have
been observed after local radiotherapy
in patients with TCC to the region of the
urinary bladder, the duration of which
also depended on the clinical situation
(whether tumour-free or not) of the
patient post therapy. (B. Unsgaard, to
be published.) It should be noted that
these patients were treated palliatively
and all succumbed to widespread meta-
stases (Tables II, VIII, X).
DISCUSSION
These results demonstrate that the
incidence and type of cytotoxicity pro-
duced by effector cell preparations from
melanoma patients are influenced by
tumour burden and therapeutic inter-
vention. The method of effector cell
preparation was shown to yield a hetero-
geneous population of lymphoid and
myeloid precursor cells from certain pa-
tient groups, particularly those with
metastatic tumour. Detailed analyses of
the composition of effector cell prepara-
tions used in in vitro assays for CMI
from patients in different clinical situa-
tions have not previously been reported.
The high incidence of nonspecific effects
on histogenically diverse targets observed
with preparations from patients with
metastases could implicate non-lympho-
cytic cells in these effects. Neutrophils,
eosinophils and myeloid precursor cells
are known to be rich in hydrolytic
enzymes. Such enzymes have been shown
to exert a powerful cytolytic effect on
a variety of mammalian target cells in
vitro (Edelson and Cohn, 1973). How-
ever, effector cell preparations from pa-
tients with basal cell carcinoma also
showed a significant incidence of non-
specific effects despite no obvious non-
lymphocytic contamination. Elucidation
of the role and target specificity range
of different effector cell populations in in
vitro cytotoxicity assays will require the
procurement of more homogeneous popu-
lations ofeffector cell types and standardi-
zation of preparative procedures.
Tumour specific cytotoxicity could be
quantitated in certain patients with
ocular and skin melanomata. A long-
term cell line and a primary culture
derived from metastatic skin melanomata
were compared as allogeneic targets and
found to give qualitatively comparable
results. It has previously been reported
that sera from some patients with ocular
melanoma contain antibodies which react
specifically with skin melanoma target
cells (Nairn et al., 1972; Federman,
Lewis and Clark, 1974). Our data demon-
strate cross reactivity also at the cellular
level.
The incidence of tumour specific CMI
detected in this series of melanoma
patients contrasts sharply with that
reported for patients with the same
diagnosis and in similar clinical situations
by Hellstrom et al. (1971, 1973a, b).
These authors found that the majority
of clinically cured patients had tumour
specific CMI during a 1-2 year observa-
tion period post surgery. In a similar
group of patients we have found tumour
specific C1II a rare phenomenon. Fossati
et al. (1971) reported a high incidence of
tumour specific CMI in patients 1-6
months after surgery; in the present series
we observed reactivity mainly during a 3-4
week interval after surgery. Similar re-
sults have been reported by Nairn et
al. (1972) who found no reactivity in
melanoma patients tested 2 months post
surgery.
Using similar in vitro assays, several
authors have reported a diminution of
tumour specific CMI in some melanoma
patients with disseminated disease (De
Vries etal., 1972; Hellstr6m etal., 1973a, b;
Heppner et al., 1973). Currie et al.
(1971) reported a correlation in the
incidence of CMI and extent of disease;
311B. UNSGAARD AND C. 0 TOOLE
however, this was not apparent after
more extensive washing of effector cell
preparations (Currie, 1973). Cochran et
al. (1973) using a leucocyte migration
inhibition assay, found correlations with
the stage of disease. In the present
series, tumour specific reactions were
detected only in patients with localized
disease while patients with disseminated
melanoma were either nonreactive or
showed nonspecific cytotoxicity. It
should be noted that all effector cell
preparations tested were washed a mini-
mum of 6 times during preparation.
The incidence of tumour specific CMI in
patients with TCC of the bladder has
been shown to correlate with extent of
disease, patients with localized tumours
showing the highest incidence (O'Toole et
al., 1972a, b, 1973a).
Comparisons ofthe clinical significance
of the incidence of CMI in patients with
melanoma, reported by different authors,
cannot at present be made due to the
disparity in methods of effector cell
preparation, effector: target cell ratio and
probable heterogeneity.
Significant clinical correlations have,
however, been reported between the level
of specific serum blocking factor (SBF)
for CMI, in vitro and extent of disease
(Hellstrom et al., 1973b). In vitro quanti-
tation of tumour specific CMI and its
relation to the serum levels of SBF
remain to be determined. However, a
correlation between the level of tumour
specific antibodies and the extent of
disease has been documented in patients
with malignant melanoma (Morton et
al., 1968, 1971; Lewis et al., 1969).
Local radiotherapy and surgery have
been shown to modify tumour specific
CMI in patients with TCC of the bladder
(O'Toole et al., 1972a, b, 1973a). The
maintenance of CMI in these patients
was shown to be dependent on the
presence of critical amounts of tumour
material in the body. Successful re-
moval of tumour by surgery led to
the disappearance of specific CMI within
2-3 weeks post surgery. The majority
of tumour-free melanoma patients tested
at intervals greater than 1 month post
surgery in this series also lacked tumour
specific CMI. Radiotherapy in patients
with TCC could induce a specific CMI in
some cases which were previously non-
reactive. This was observed also in a
single melanoma case in the present
series.
Patients with TCC given preoperative
radiotherapy were shown to maintain
tumour specific CMI for a period of
several months after surgery (O'Toole et
al., 1972b, 1973a). This effect was not
observed in the melanoma patients given
preoperative radiotherapy. Irradiation
technique, duration, time interval between
radiotherapy and surgery and the actual
tumour volume irradiated could determine
these differences.
Tumour specific CMI has not been
observed in patients with TCC who have
remained tumour-free during a 1-12 year
period after radiotherapy. However, re-
sponses were detected in patients who
developed local recurrences after therapy
(O'Toole et al., 1973a). The relevance of
tumour specific CMI to the aetiology of
disease in the 2 melanoma patients who
showed tumour specific reactionis 2 and
12-13 years after therapy respectively,
remains to be elucidated.
Patients with metastatic melanoma
given palliative local radiotherapy to
the axillary or inguinal region in doses
of 4000-4960 rad were seen to develop
pronounced lymphopenia when tested
2-14 days aftertreatment. Similareffects
have been observed after local radio-
therapy (Thomas et al., 1971; Stjernsward
et al., 1973; Chee, Ilberry and Rickinson,
1974) to other areas of the body.
We wish to thank Mrs Anna-Greta
Goransson and Mrs Margareta Karlsson
for excellent technical assistance. The
work was supported from Grant no.
73 :213 from the Swedish Cancer Society
and The Jonkoping Cancer Fund for
Clinical Research.
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APPENDIX
Therapy used for malignant melanoma:
Surgery.-The primary tumour was ex-
cised in patients with stage I skin melanoma.
Stage II patients were treated by local
excision of the primary and dissection of the
draining lymph nodes. For stage III the
primary tumour was excised to reduce
tumour burden, and then cytostatics and/or
external radiation were given palliatively.
Radiotherapy.-Stage I malignant melan-
oma of the skin is treated at this hospital by
preoperative radiotherapy. This was given
with a Dermopan 2 unit operated at 10-50
kV, 25 mA, either without filter or with
0 3-1 mm Al. The total skin dose was
10,000 rad, given with a margin, followed
24-120 h later by excision ofthe treated area
with about 1 cm margin.
Therapy and clinical details of patients
with transitional cell carcinoma of the
urinary bladder:
Patients receiving radiotherapy were
given either 60Co teletherapy or betatron
18 MeV roentgen. Two patients received
4000-4200 rad preoperatively and 12 had
full dose treatment of 6270-6725 rad.
Patients treated surgically had transurethral
resection only or total cystectomy 1 month
after radiotherapy. The clinical staging of
APPENDIX TABLE I.-Total Patients with
Melanoma Tested
Site of origin
Eye
Head and neck
Upper limb
Trunk
Lower limb
Vulva
Unknown*
Total
Female Male
3 3
3
2 2
3 6
6 2
1
2
18 15
Total
6
3
4
9
8
1
2
33
* Patients with generalized tumour process.
Site of primary tumour unknown.
APPENDIX TABLE II.-Summary of Clinical Data on Patients with Malignant
Melanoma or Melanosis of the Eye
Patient Age Sex Situation
S.T. 58 Female Epibulbar tumour. 14 years history of a malignant Before enu
melanoma in the conjunctiva. Several recurrences eye.
with local excisions. At the time of test local recur-
rence with 2 tumours, 4 mm in diameter, surrounded
by small satellites
L.B. 46 Male Epibulbar location. Several years duration of melan- Untreated.
osis in the conjunctiva
F.L. 73 Male Intraocular tumour. 5 years history of an intraocular 3 months
tumour in the right eye. Enucleation was per- tion. C
formed. PAD showed a malignant melanoma, 10 mated as
mm in diameter, in the choroid with detachment of
the retina. The tumour was composed oflarge pleo-
morphic cells with large ovoid nuclei. Few mitoses.
Pigment content was sparse
F.E. 71 Female Intraocular tumour. 2 months history of decreased The first t(
sight of left eye. Intraocular tumour was revealed. before en
Enucleation of the eye. PAD showed malignant second t
melanoma, 9 mm in diameter and 4 mm in height, after enui
growing in the choroid, partly infiltrating into the ically est
sclera, but without breaking through the sclera. The mour-fre
tumour was composed of slender spindle shaped cells
with fusiform nuclei. Abundance of melanin con-
taining macrophages
M.A. 8 Female Intraocular tumour. 6 months history of a growing Beforethe I
brown pigmented spot in the iris. Partial iridec- tion.
tomy. PAD showed malignant melanoma with
doubtful radicality. Removal of the eye. PAD
showed local recurrence of malignant melanoma in
the iris and local metastases to the anterior chamber
F.S. 74 Male Intraocular tumour. Malignant melanoma of the iris Untreated.
at time of test
Lcleation of the
after enuclea-
Clinically esti-
s tumour-free.
est was made
lucleation. The
best 4 months
cleation. Clin-
timated as tu-
,e.
primary opera-
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APPENDIX TABLE III.-Number and Clini-
cal Stage Distribution of Patients with
Malignant Melanoma in the Skin
Classi- No. of
fication patients
Stage I Localized melanoma confined to 18
the skin. Local recurrences
and nearby deposits in cu-
taneous lymphatics are in-
cluded
Stage II Cases with regional lymph node 4
metastases confined to one
gland station only
Stage III Metastatic involvement of 2 or 2
more groups of glands, and
cases with distant metastases
evincing generalized tumour
process
TCC (Table IV) is that proposed by UICC
(1963); and the histological grading used
was according to Bergkvist et al. (1965).
The 29 patients with TCC were distributed
according to tumour grade as follows:
grade I, 2 cases; grade II, 8 cases; grade III,
13 cases and grade IV, 6 cases.
Age distribution of patients and controls
used in this study:
Patients with malignant melanoma of
the skin were aged 28-85 (mean 53) years.
Those with ocular tumours 8-74 (mean 55)
years. Patients with basal cell carcinoma
56-85 (mean 67) years. Patients with TCC
57-82 (mean 67) years. Normal controls
20-59 (mean 38) years.
APPENDIX TABLE IV.-Clinical Controls
Tested after
Irradiation Surgery Irradiation Surgery
Clinical situation:
Diagnosis
TCC tumour stage
TI
T2*
T3t
T4:
Transitional cell ca (TCC)
Total
Ca renal pelvis
Ca prostate
Ca rectum with metastases
urinary bladder
Ca skin
Histiocytoma skin
Normal healthy
Untreated Tumour-free
2
4
7
9
5
13
1
1
1
10
3
14 3
2
1
Tumour present
2
6
2
10
1
1
* 2 patients were tested 3 times after irradiation.
1 patient was tested before and after irradiation.
1 patient was tested during irradiation and after cystectomy.
t 3 patients were tested twice after irradiation.
1 patient was tested before and after irradiation.
I This patient was tested twice.
§ 1 patient tested before and after local radiotherapy.
A
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APPENDIX TABLE V.-Effect of Local Radiotherapy on Peripheral Blood Leucocyte and
Lymphocyte Counts in Patients with Malignant Melanoma of the Skin
Tumour Tumour Total Total
stage site Time of test leucocytes/mm3 lymphocytes/mm3
II S.M., 49 years, Lower limb Untreated 5200 2652
female 48 h after 4960 rad given 4100 1107
over 58 days to inguinal
region
2 weeks post irradiation 3100 372
II P.G., 49 years, Truncus Untreated 9400 1974
male 48 h after 4000 rad given 5200 260
over 21 days to the axilla
III A.R., 53 years, Truncus Untreated 9500 3610
male 48 h after 4000 rad given 5400 594
over 15 days to the axilla
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